Pharma companies must start preparing its NICE submission at the time of making the regulatory subm...
Read moreA best practice guide for companies seeking parallel scientific HTA advice has been published by the...
Read moreWhether ICER will become an integral part of the US healthcare landscape in the future remains to be...
Read moreThis report highlights some "quick wins" that member states can quickly and easily adopt to decrease...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read moreThe methodology to be used within the cost-effectiveness HTA evaluations is likely to be based on a ...
Read moreSome governments have looked to collective procurement with other countries, to in theory result in ...
Read moreThere are now European platforms for seeking early scientific advice with multiple payer organisatio...
Read moreThe aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreBased on the current clinical data, the PCSK9 inhibitors are a vital new treatment option for patien...
Read more